Seven Fleet Capital Management LP Makes New Investment in Zentalis Pharmaceuticals, Inc. $ZNTL

Seven Fleet Capital Management LP purchased a new position in shares of Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) in the 1st quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 110,000 shares of the company’s stock, valued at approximately $257,000. Seven Fleet Capital Management LP owned approximately 0.15% of Zentalis Pharmaceuticals as of its most recent filing with the Securities and Exchange Commission (SEC).

Other large investors also recently modified their holdings of the company. CTC Alternative Strategies Ltd. acquired a new stake in shares of Zentalis Pharmaceuticals during the 1st quarter valued at $29,000. ADAR1 Capital Management LLC increased its holdings in Zentalis Pharmaceuticals by 80.8% in the 1st quarter. ADAR1 Capital Management LLC now owns 144,636 shares of the company’s stock worth $338,000 after purchasing an additional 64,636 shares in the last quarter. OMERS ADMINISTRATION Corp acquired a new position in Zentalis Pharmaceuticals in the 1st quarter worth about $112,000. Sei Investments Co. raised its position in Zentalis Pharmaceuticals by 14.6% in the first quarter. Sei Investments Co. now owns 191,551 shares of the company’s stock valued at $448,000 after purchasing an additional 24,451 shares during the last quarter. Finally, State of Wyoming bought a new position in Zentalis Pharmaceuticals in the first quarter valued at about $67,000.

Zentalis Pharmaceuticals Trading Down 3.7%

Shares of ZNTL opened at $4.74 on Friday. The stock has a market capitalization of $337.44 million, a P/E ratio of -2.74 and a beta of 1.92. The firm’s fifty day simple moving average is $4.24 and its two-hundred day simple moving average is $3.55. Zentalis Pharmaceuticals, Inc. has a 12 month low of $1.21 and a 12 month high of $6.95.

Zentalis Pharmaceuticals (NASDAQ:ZNTL) last issued its quarterly earnings results on Tuesday, May 12th. The company reported ($0.50) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.49) by ($0.01). As a group, research analysts predict that Zentalis Pharmaceuticals, Inc. will post -1.83 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

ZNTL has been the topic of a number of recent research reports. Guggenheim lifted their price target on Zentalis Pharmaceuticals from $6.00 to $10.00 and gave the company a “buy” rating in a research note on Friday, April 10th. HC Wainwright reaffirmed a “buy” rating and issued a $10.00 price objective on shares of Zentalis Pharmaceuticals in a research note on Friday, May 22nd. Wall Street Zen upgraded shares of Zentalis Pharmaceuticals from a “strong sell” rating to a “sell” rating in a report on Sunday, May 31st. Mizuho started coverage on shares of Zentalis Pharmaceuticals in a research report on Friday, July 17th. They set an “outperform” rating and a $8.00 target price on the stock. Finally, Rodman & Renshaw began coverage on shares of Zentalis Pharmaceuticals in a research report on Thursday, July 23rd. They set a “buy” rating and a $11.00 target price on the stock. Four research analysts have rated the stock with a Buy rating, four have given a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, Zentalis Pharmaceuticals presently has a consensus rating of “Hold” and a consensus target price of $6.75.

Zentalis Pharmaceuticals Profile

Zentalis Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapeutics for oncology. Leveraging a proprietary structure-based drug discovery platform, the company designs selective inhibitors aimed at critical cancer targets. Zentalis’ research and development efforts center on delivering differentiated therapies that address unmet medical needs in solid tumors and hematologic malignancies.

The company’s lead product candidate, ZN-c3, is an orally administered inhibitor of the p53-MDM2 interaction, currently being evaluated in Phase I clinical trials for advanced solid tumors and hematologic cancers.